Objective: The incorporation of rituximab in immunochemotherapy has improved treatment outcomes for diffuse large B-cell lymphoma, but the prognosis for some diffuse large B-cell lymphomas remains dismal. Identification of adverse prognostic subgroups is essential for the choice of appropriate therapeutic strategy. Methods: We retrospectively investigated the impact of so-called 'double-hit' cytogenetic abnormalities, i.e. cytogenetic abnormalities involving c-MYC co-existing with other poor prognostic cytogenetic abnormalities involving BCL2, BCL6 or BACH2, on treatment outcomes for 93 consecutive diffuse large B-cell lymphoma patients. Results: According to the revised international prognostic index, no patients were cytogenetically diagnosed with double-hit lymphomas in the 'very good' risk group or in the 'good' risk group, while 5 of 33 patients had double-hit lymphomas in the 'poor' risk group. All the double-hit lymphoma patients possessed both nodal and extranodal involvement. The overall complete response rate was 89.3%, overall survival 87.1% and progression-free survival 75.8% over 2 years (median observation period: 644 days). The complete response rates were 93.2% for the non-double-hit lymphoma patients and 40.0% for the double-hit lymphoma patients. Significantly longer progression-free survival and overall survival were observed for the 'very good' and the 'good' risk patients than for the 'poor' risk patients. Moreover, the progression-free survival of double-hit lymphoma was significantly shorter than that of the non-double-hit lymphoma 'poor' risk patients (P ¼ 0.016). In addition, the overall survival of the double-hit lymphoma patients also tended to be shorter than that of the non-double-hit lymphoma 'poor' risk group. Conclusions: The diagnosis of double-hit lymphoma can help discriminate a subgroup of highly aggressive diffuse large B-cell lymphomas and indicate the need for the development of novel therapeutic strategies for double-hit lymphoma.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and is highly heterogeneous in terms of morphological findings, clinical features and cytogenetic and molecular abnormalities (1) . Although the incorporation of rituximab into anthracyclinebased systemic chemotherapy protocols, such as R-CHOP, has dramatically improved long-term outcomes for DLBCL, outcomes for some DLBCL patients remain dismal (2, 3) . Identification of additional prognostic factors for the prediction of outcomes for DLBCL patients and that are easy to identify in daily clinical practice is thus essential for the choice of appropriate therapeutic strategy.
The classical international prognostic index (IPI) (4) and the subclassification of DLBCL into germinal center B-like DLBCL (GCB type) and non-GCB type on the basis of expression patterns of CD10, BCL6 and MUM1 were highly predictive for the outcome of DLBCLs before the era of rituximab (5, 6) , but their prognostic strength has been diminished by the emergence of rituximab-containing immunochemotherapy. The revised IPI (R-IPI), which classifies DLBCLs into three risk groups, 'very good', 'good' and 'poor', by re-evaluating and redistributing the prognostic factors used in the classical IPI, has been widely used for the prediction of DLBCL prognosis in the rituximab era (3) . However, the treatment outcome of some patients with DLBCL those with highly aggressive phenotypes are rather worse than that expected by R-IPI.
Recurrent chromosomal translocations in DLBCLs, involving c-MYC, BCL2 and BCL6, have been reported (7 -11) . The c-MYC translocation has been detected in 3 -15% of DLBCLs and is reportedly associated with adverse prognosis (11 -18) . An important discovery is that c-MYC gene rearrangement is rarely found to be the sole genetic abnormality but often co-occurs with complex cytogenetic abnormalities, such as concurrent rearrangements of BCL2 and/or BCL6 (11) . DLBCLs, which possess chromosomal aberrations affecting c-MYC at chromosome 8q24 in combination with another recurrent chromosomal aberration, such as t(14;18) involving BCL2, have recently become the subject of heightened attention because of their extremely poor prognosis, and are commonly known as 'double-hit' lymphomas (DHLs) (19 -23) . In the study, we retrospectively investigated the treatment outcome for 93 consecutive patients who were histopathologically diagnosed with DLBCL and treated at our institute. The aim of our study was to evaluate the impact of the diagnosis of DHL on the outcome in comparison with the findings of the R-IPI study.
PATIENTS AND METHODS

PATIENTS
This study involved 93 patients with histological diagnosis of DLBCL who were treated at Kyoto Prefectural University of Medicine between January 2006 and February 2011. All patients met the criteria for IPI and R-IPI evaluations (3).
MORPHOLOGICAL AND IMMUNOPHENOTYPIC STUDIES
Histological analysis of the materials from each patient was performed independently by two pathologists. To define molecular subtypes of DLBCL, i.e. GCB type and non-GCB type (6), paraffin-embedded sections of each sample were immunostained with monoclonal antibodies against CD10 (Leica Biosystems, New Castle, UK), BCL6 (Leica Biosystems) and MUM-1 (DAKO, Glostrup, Denmark).
CYTOGENETIC ANALYSES
Cytogenetic abnormalities were assessed by routine analysis using G-banding for all patients at their diagnosis. For patients with chromosomal aberration at 8q24 detected by G-banding, we also performed fluorescent in situ hybridization (FISH) and spectral karyotyping (SKY) analyses for more detailed chromosomal data. Briefly, for double-color 
RESULTS
PATIENTS' BACKGROUND
Patients' background is summarized in Table 1 . The median age at diagnosis was 68 years (range: 26 -92). According to R-IPI criteria, 10 patients (10.8%) were classified as 'very good' risk, 50 (53.7%) as 'good' risk and 33 (35.5%) as 'poor' risk. Five patients (5.4%) possessed a chromosomal breakpoint affecting c-MYC at 8q24, and all of them were cytogenetically diagnosed with DHL with concomitant chromosomal abnormalities involving BACH2 rearrangements in one patient, and BCL2 and BCL6 rearrangements in two each. All these five DHL patients were classified as 'poor' risk (Tables 1 and 2 ). In 10 'very good' risk patients, 50% patients had extranodal involvement. In 50 'good' risk patients, 44% had only nodal involvement and 28% had only extranodal involvement, while 28 had both nodal and extranodal involvement. In 33 'poor' risk patients, 6.8% had only nodal involvement and 9.1% had only extranodal involvement, while 75.8% had both nodal and extranodal involvement (Table 3) .
HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES WITH DHLS
By the conventional histologic study using hematoxylin and eosin staining, two of five DHLs (Pts 1 and 4) were shown to have typical DLBCL morphology, while other three DHLs (Pts 2, 3 and 5) exhibited Burkitt-like morphology with medium-sized lymphoma cells and 'starry-sky' appearance ( Fig. 1 and Table 2 ). In addition, four of five DHLs were analyzed for the molecular classifications by immunohistochemistry (6) and three of four were diagnosed as non-GCB type (Table 2 ).
TREATMENT AND TREATMENT OUTCOME All patients were treated with R-CHOP-based chemotherapy (i.e. R-CHOP with/without irradiation or surgical resection) as initial treatment except for two, one of whom received rituximab monotherapy and the other radiation monotherapy because of advanced age (both over 85 years old). Five 'good' risk patients received sequential short course R-CHOP plus radiation therapy for localized disease, while three 'poor' risk patients received radiation as additional therapy following six to eight courses of R-CHOP. Six patients underwent surgery for the diagnostic resection of localized tumor with subsequent chemotherapy. Only one non-DHL patient received up-front high-dose chemotherapy (HDCT) combined with autologous peripheral blood stem cell transplantation (aPBSCT) following induction chemotherapy with R-CHOP, and maintained complete response (CR) at the time of this analysis (Table 1) . With a median follow-up period of 644 days (range: 24 -2084 days), the overall 2-year PFS was 75.8% and the 2-year OS 87.1%. Table 4 summarizes the treatment responses and outcomes by R-IPI risk group for 93 patients. CR was attained for 84 patients (90.3%), and the CR rates tend to be higher for 'very good' and 'good' risk groups than for the 'poor' risk group. Relapse rate for all the patients was 19.4%, the 'poor' risk patients tending to show a higher incidence of relapse (39.4%). Of the five DHL patients, only two (40.0%) achieved CR and all but one had progressed or eventually relapsed.
Significantly longer PFS was attained by 'very good' risk and 'good' risk patients than by 'poor' risk patients (P ¼ 0.011 and P , 0.001, respectively), and PFS of 'very good' risk and 'good' risk patients showed no significant difference (P ¼ 0.296). Similarly, the OS of the 'poor' risk patients was significantly shorter than that of 'very good' risk patients (P ¼ 0.050) and 'good' risk patients (P , 0.001). By the end of the study period, DLBCL patients in the 'very good' risk group were all alive without any progression (Fig. 2) . Both OS and PFS of DHLs were significantly shorter than those of non-DHL patients (P , 0.001). The median OS and the PFS of DHLs were 162 and 127 days, respectively, while those of non-DHL patients were not reached. An important finding was that the PFS of DHL patients was significantly shorter than that of non-DHL 'poor' risk patients (P ¼ 0.016). In addition, the OS of the DHLs also tended to be shorter than that of the non-DHL 'poor' risk group (P ¼ 0.153), although the difference was not statistically significant, probably because of the small number of patients (Fig. 3) .
DISCUSSION
Although first-line chemotherapy with rituximab including immunochemotherapy cured many of the DLBCL patients in our series, the prognosis for some of them remains dismal. The identification of such high-risk patients at diagnosis may lead to alternative treatment strategies. Although risk evaluation using R-IPI criteria resulted in a clear classification of the outcomes for DLBCL patients as shown in Fig. 1 , a subpopulation of patients with DLBCL showed a rather rapid and aggressive clinical course which could not be accurately predicted by means of R-IPI criteria.
DHLs reportedly account for 0 -12% of DLBCLs, and those patients often present with poor prognostic parameters, including elevated lactate dehydrogenase, bone marrow (BM) and central nervous system (CNS) involvement, and a high IPI score (19 -23) . In our study, DHLs constituted 5.4% of all the DLBCL patients and all of them were classified as R-IPI 'poor' risk groups. Of the five DHL patients, two featured CNS invasion, BM invasion was observed in three and other extranodal invasions, such as pleural effusion, in four and all the five had at least one extranodal lesion. The treatment outcomes for these five DHL patients were extremely unfavorable compared with those for the non-DHL patients, even in the cohort of the R-IPI 'poor' risk group. The clinical features of the DHL patients in our study were thus comparable to those of the DHL patients in previous studies. An important finding was that the PFS of the DHL patients was significantly shorter than that of the non-DHL 'poor' risk cases (P ¼ 0.016), and that the OS of the DHL patients tended to be shorter than that of the non-DHL 'poor' risk patients (P ¼ 0.153). These results suggest that the diagnosis of DHL could lead to identify rather highly aggressive patients even in the 'poor' R-IPI risk patients (Fig. 3) . The high CR rates and low relapse rates for most of the 'very good' risk as well as 'good' risk DLBCL patients in our study suggest that conventional R-CHOP-based systemic chemotherapy is in principle optimal as first-line chemotherapy. Further, a high CR rate indicated that R-CHOP-based systemic chemotherapy is optimal as the first-line treatment for non-DHL 'poor' risk patients, but 20% of the non-DHL 'poor' risk patients failed to attain CR and about one-third of the non-DHL 'poor' risk patients relapsed. In total, approximately one-half of the non-DHL 'poor' risk patients failed to attain CR with R-CHOP-based systemic chemotherapy only. These outcomes indicate that up-front HDCT as consolidation therapy may be a suitable option for some non-DHL 'poor' risk patients. In addition, close monitoring of treatment response is mandatory in the treatment of non-DHL 'poor' risk patients so that indications for the use of alternative, more intensive treatment are not missed. There is thus an urgent need for verification of prognostic factors for discriminating between higher risk non-DHL 'poor' risk patients and lower risk non-DHL 'poor' risk patients. R-CHOP-based therapy was not effective for the DHL patients compared with the non-DHL patients in our study. Higher efficacy may be expected from using more intensive systemic chemotherapies, such as R-CODOX-M/ IVAC, as the initial therapy for DHLs; however, so far there have been no data which support their effects on DHLs. Also, because c-MYC overexpression potently modulates 1040 Double-hit lymphomas in rituximab era DNA damage response and causes multidrug resistance by overexpressing drug transporter molecules (26, 27) , intensive chemotherapy consisting of standard anticancer agents may not always be beneficial. Another possible strategy may involve the development of a novel molecular targeted therapy. The synergistic molecular effect of c-MYC and BCL2 on lymphomagenesis is well known (28, 29) . Sasaki et al. (30) developed cell lines from DHL Cases #2 and #3 (Table 2) , and have shown that these cell lines are highly addictive to BCL2, but not to c-MYC. Especially important is that the dual inhibition of c-MYC and BCL2 synergistically killed those cell lines in in vitro assays. Moreover, it has been reported that genomic complexity is associated with survival in lymphomas with MYC rearrangement (31) . In fact, the patients with DCAs in our study showed rather complex chromosomal abnormalities that may induce various additional genetic alterations, so that there could be an as yet unknown target molecule to which DHL lymphoma cells are addicted. Several novel agents, such as enzastaurin, bortezomib, bevacizumab, lenalidomide, bendamustine, mTOR inhibitors, Syk inhibitors and histone deacetylase inhibitors, are under development for the treatment of DLBCL (32 -40) . It is anticipated that these new agents will further improve the treatment outcome of DLBCLs including DHLs.
In conclusion, our study showed that the diagnosis of DHL can help identify highly aggressive patients, who are difficult to be treated with conventional R-CHOP. Furthermore, the concept and the role of first-line treatment for non-DHL 'poor' risk patients and DHL patients may well differ. The development of alternative therapy protocols is urgently needed for DHLs.
